Acasti Pharma Revenue and Competitors

Laval,

Location

$54.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Acasti Pharma's estimated annual revenue is currently $1.6M per year.(i)
  • Acasti Pharma's estimated revenue per employee is $77,500
  • Acasti Pharma's total funding is $54.9M.

Employee Data

  • Acasti Pharma has 20 Employees.(i)
  • Acasti Pharma grew their employee count by -31% last year.

Acasti Pharma's People

NameTitleEmail/Phone
1
COOReveal Email/Phone
2
ControllerReveal Email/Phone
3
Director - Quality and ComplianceReveal Email/Phone
4
President/CEO/SecretaryReveal Email/Phone
5
Assistant Gestionnaire de Projets - Développement de procédé et productionReveal Email/Phone
6
Finance Consultant - ConsultantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Acasti Pharma?

Acasti est un innovateur biopharmaceutique dont les activités sont axées sur la recherche, le développement et la commercialisation de médicaments sur ordonnance au moyen d?acides gras oméga-3 tirés de l?huile de krill. Les acides gras oméga-3 font l?objet de nombreuses données cliniques probantes d?innocuité et d?efficacité pour diminuer les triglycérides chez les patients atteints d?hypertriglycéridémie. Une étude de marché commandée par Acasti suggère qu?il existe un besoin important dans le marché visant un traitement à base d?oméga-3 efficace, sûr et bien absorbable ayant une incidence positive sur les principaux lipides associés au risque de maladie cardiovasculaire. Depuis août 2008, Acasti se concentre à répondre à cet important besoin non comblé sur le marché. Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need.

keywords:N/A

$54.9M

Total Funding

20

Number of Employees

$1.6M

Revenue (est)

-31%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Acasti Pharma News

2022-04-20 - Short Interest in Acasti Pharma Inc. (NASDAQ:ACST) Drops ...

ACST has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Acasti Pharma from a “sell” rating to a “hold...

2022-03-30 - Acasti Pharma Appoints Healthcare Industry Leader Michael L ...

Acasti is an advanced- stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

2022-03-22 - Acasti Pharma Announces Patents for GTX-104 in Europe ...

Acasti is an advanced- stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.8M2018%N/A
#2
$4.5M205%N/A
#3
$2M20N/AN/A
#4
$5.2M21-54%N/A
#5
$2.5M2222%N/A